The Technical Analyst
Select Language :
Immutep Limited [IMMP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Immutep Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals

Immutep Limited is listed at the  Exchange

-2.11% $2.34

America/New_York / 28 mar 2024 @ 12:47


Immutep Limited: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 292.57 mill
EPS: -0.250
P/E: -9.36
Earnings Date: Aug 28, 2024
SharesOutstanding: 125.03 mill
Avg Daily Volume: 0.131 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Sell
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebitn/an/an/an/an/an/a
Asset n/an/an/an/an/an/a
Debtn/an/an/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -9.36 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.59x
Company: PE -9.36 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.0461
(-98.03%) $-2.29
Date: 2024-03-28
Expected Trading Range (DAY)

$ 2.15 - 2.49

( +/- 7.46%)
ATR Model: 14 days

Forecast: 14:26 - $2.38

Live Trading Signals (every 1 min)

Forecast 1: 12:56 - $2.32
Forecast 2: 13:46 - $2.36
Forecast 3: 14:26 - $2.38
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.34 (-2.11% )
Volume 0.0518 mill
Avg. Vol. 0.131 mill
% of Avg. Vol 39.62 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Immutep Limited

Last 12 Months

Last 12 months chart data with high, low, open and close for Immutep Limited

RSI

Intraday RSI14 chart for Immutep Limited

Last 10 Buy & Sell Signals For IMMP

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Immutep Limited

IMMP

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Last 10 Buy Signals

Date Signal @
INTUMar 28 - 12:45$651.22
CARMar 28 - 12:45$122.87
FLIPUSDMar 28 - 12:435.36
YFIIUSDMar 28 - 12:42$617.65
REGNMar 28 - 12:43$961.16
TEAMMar 28 - 12:43$194.76
RTYUSDMar 28 - 12:342 154.70
WULFMar 28 - 12:42$2.75
HUTMar 28 - 12:42$11.69
VKTXMar 28 - 12:41$83.30

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.